OncologyTube Professional - Patients Click Here
248,704 video views
moasc: Videos
00:39
Yung Lyou, MD, UC Irvine Health, talks about Selecting Patients for Adjuvant Pancreatic Treatment | Determine Who Has Better Performance Status at MOASC 2018
by:moasc | 5 views
00:44
Fa-Chyi Lee, MD, UC Irvine Health, talks about the Major Impact from HIPEC is Insurance Reimbursement | Insurance Companies Feel Impact of Approval Rejection at MOASC 2018
by:moasc | 16 views
02:37
Edward L. Nelson, MD, UC Irvine Health explains Number of Molecular Targets Are Overwhelming Practitioners | Practitioners Must Know What is Supported by Literature & Field at MOASC 2018
by:moasc | 3 views
01:16
John P. Fruehauf, MD, UC Irvine Health, explains New Agents for BRAF-MEK Inhibition | Binimetinib/Enc​orafenib at MOASC 2018
by:moasc | 8 views
00:42
Nataliya Mar, MD, UC Irvine Health, Addressing Non-Clear Cell Histology | Did Not Come Across Any Trials at MOASC 2018
by:moasc | 5 views
00:55
Rita Sanghvi Mehta, MD, UC Irvine Health, explains High-Dose Fulvestrant Vs. Loading Dose | Loading Dose Prevents Early Progressions at MOASC 2018.
by:moasc | 5 views
01:26
Yung Lyou, MD, UC Irvine Health, talks PRODIGE 24 Showed FOLFIRINOX has Benefits | FOLFIRINOX was Compared to Single-Agent Gemcitabine at MOASC 2018
by:moasc | 5 views
01:08
Edward L. Nelson, MD, UC Irvine Health explains Whether to ReBiopsy a Tumor | Give Practitioners Understanding of Modalities at MOASC 2018
by:moasc | 5 views
00:52
Fa-Chyi Lee, MD, UC Irvine Health, talks about the Negative Results from HIPEC Study | Surgery May Still Have Role at MOASC 2018
by:moasc | 13 views
00:56
John P. Fruehauf, MD, UC Irvine Health, explains KEYTRUDA & Role in Stage 4 Melanoma | Immunotherapy has Long-Term Benefits After Treatment at MOASC 2018
by:moasc | 18 views
dsfsd